Publications by authors named "F V Fossella"
Background: Neoadjuvant immune checkpoint inhibitors (ICIs) have improved survival outcomes compared with chemotherapy in resectable non-small cell lung cancer (NSCLC). However, the impact of actionable genomic alterations (AGAs) on the efficacy of neoadjuvant ICIs remains unclear. We report the influence of AGAs on treatment failure (TF) in patients with resectable NSCLC treated with neoadjuvant ICIs.
View Article and Find Full Text PDFIntroduction: Germline mutations driving lung cancer have been infrequently reported in the literature, with EGFR T790M being a known germline mutation identified in 1% of NSCLCs. Typically, a somatic EGFR mutation is acquired to develop lung adenocarcinoma. Osimertinib has become a standard-of-care treatment for EGFR T790M-positive lung cancer.
View Article and Find Full Text PDFIntroduction: amplification is a known resistance mechanism to tyrosine kinase inhibitor (TKI) treatment in -mutant NSCLC. Dual EGFR-MET inhibition has been reported with success in overcoming such resistance and inducing clinical benefit. Resistance mechanisms to dual EGFR-MET inhibition require further investigation and characterization.
View Article and Find Full Text PDFArticle Synopsis
- A study was done to see if adding immunotherapy to a common lung cancer treatment (SABR) would be better than using SABR alone in patients with early-stage lung cancer.
- The trial involved 156 people, where half received just SABR and the other half received SABR with immunotherapy (called I-SABR).
- After about 33 months, the results showed that those who got I-SABR had a much better chance of not having their cancer return compared to those who received just SABR.
Purpose: To compare the efficacy and toxicity of pemetrexed versus docetaxel in patients with advanced non-small-cell lung cancer (NSCLC) previously treated with chemotherapy.
Patients And Methods: Eligible patients had a performance status 0 to 2, previous treatment with one prior chemotherapy regimen for advanced NSCLC, and adequate organ function. Patients received pemetrexed 500 mg/m intravenously (IV) day 1 with vitamin B, folic acid, and dexamethasone or docetaxel 75 mg/m IV day 1 with dexamethasone every 21 days.